

# Liu-Cheng Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3597959/publications.pdf>

Version: 2024-02-01

23  
papers

1,019  
citations

567281

15  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1666  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nano-enabled delivery of EGCG ameliorates silica-induced pulmonary fibrosis in rats. <i>Toxicology</i> , 2022, 469, 153114.	4.2	10
2	Enhancing antioxidant, antimicrobial and anti-NSCLC activities of (â€)â€epigallocatechin gallate encapsulated poly(butylâ€â€cyanoacrylate) nanowires applications in dietary supplements. <i>International Journal of Food Science and Technology</i> , 2021, 56, 3367-3377.	2.7	5
3	Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 111-124.	4.3	9
4	Trends of complications in patients with Parkinsonâ€™s disease in seven major cities of China from 2016 to 2019. <i>International Clinical Psychopharmacology</i> , 2021, 36, 274-278.	1.7	5
5	Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review. <i>Integrative Medicine Research</i> , 2021, 10, 100778.	1.8	7
6	Efficacy and potential mechanisms of Chinese herbal compounds in coronavirus disease 2019: advances of laboratory and clinical studies. <i>Chinese Medicine</i> , 2021, 16, 130.	4.0	9
7	Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110641.	5.6	44
8	Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in <i>Helicobacter pylori</i> eradication. <i>Clinical and Experimental Medicine</i> , 2020, 20, 609-614.	3.6	3
9	The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 738-743.	0.3	16
10	Nrf2 antioxidant pathway suppresses Numb-mediated epithelialâ€mesenchymal transition during pulmonary fibrosis. <i>Cell Death and Disease</i> , 2018, 9, 83.	6.3	87
11	Activation of Wnt/ $\beta$ -catenin signalling is required for TGF $\beta$ /Smad2/3 signalling during myofibroblast proliferation. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1545-1554.	3.6	70
12	Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects. <i>Journal of Ethnopharmacology</i> , 2017, 198, 45-63.	4.1	98
13	Astragaloside IV Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition. <i>Frontiers in Pharmacology</i> , 2017, 8, 513.	3.5	45
14	Benefits of the active agents from Yupingfeng for pulmonary fibrosis. <i>Lungs and Breathing</i> , 2017, 1, .	0.1	0
15	Nrf2 inhibits epithelial-mesenchymal transition by suppressing snail expression during pulmonary fibrosis. <i>Scientific Reports</i> , 2016, 6, 38646.	3.3	85
16	Total Glucosides of Danggui Buxue Tang Attenuate BLM-Induced Pulmonary Fibrosis via Regulating Oxidative Stress by Inhibiting NOX4. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-10.	4.0	40
17	High-Mobility Group Box 1 Mediates Epithelial-to-Mesenchymal Transition in Pulmonary Fibrosis Involving Transforming Growth Factor- $\beta$ /Smad2/3 Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 302-309.	2.5	60
18	Inositol-requiring protein 1 â€ X-box-binding protein 1 pathway promotes epithelialâ€mesenchymal transition via mediating snail expression in pulmonary fibrosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 65, 230-238.	2.8	28

#	ARTICLE	IF	CITATIONS
19	Total glycosides of Yupingfeng protects against bleomycin-induced pulmonary fibrosis in rats associated with reduced high mobility group box 1 activation and epithelialâ€“mesenchymal transition. <i>Inflammation Research</i> , 2015, 64, 953-961.	4.0	26
20	Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. <i>Phytomedicine</i> , 2015, 22, 111-119.	5.3	51
21	Functions of Galectin-3 and Its Role in Fibrotic Diseases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 336-343.	2.5	209
22	Total polysaccharide of <i>Yupingfeng</i> protects against bleomycin-induced pulmonary fibrosis <i>via</i> inhibiting transforming growth factor- $\beta$ 1-mediated type I collagen abnormal deposition in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1786-1795.	2.4	27
23	Emerging role of <i>HMGB1</i> in fibrotic diseases. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 2331-2339.	3.6	85